Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Apr 27;19(1):81.
doi: 10.1186/s13075-017-1289-x.

Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis

George W Reed  1   2 , David H Collier  3 , Andrew S Koenig  4 , Katherine C Saunders  5 , Dimitrios A Pappas  5   6 , Heather J Litman  5 , Joel M Kremer  5   7 , Sameer Kotak  4
Affiliations
Observational Study

Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis

George W Reed et al. Arthritis Res Ther. .

Abstract

Background: We examined models to predict disease activity transitions from moderate to low or severe and associated factors in patients with rheumatoid arthritis (RA).

Methods: Data from RA patients enrolled in the Corrona registry (October 2001 to August 2014) were analyzed. Clinical Disease Activity Index (CDAI) definitions were used for low (≤10), moderate (>10 and ≤22), and severe (>22) disease activity states. A Markov model for repeated measures allowing for covariate dependence was used to model transitions between three (low, moderate, severe) states and estimate population transition probabilities. Mean sojourn times were calculated to compare length of time in particular states. Logistic regression models were used to examine impacts of covariates (time between visits, chronological year, disease duration, age) on disease states.

Results: Data from 29,853 patients (251,375 visits) and a sub-cohort of 9812 patients (46,534 visits) with regular visits (every 3-9 months) were analyzed. The probability of moving from moderate to low or severe disease by next visit was 47% and 18%, respectively. Patients stayed in moderate disease for mean 4.25 months (95% confidence interval: 4.18-4.32). Transition probabilities showed 20% of patients with low disease activity moved to moderate or severe disease within 6 months; >35% of patients with moderate disease remained in moderate disease after 6 months. Results were similar for the regular-visit sub-cohort. Significant interactions with prior disease state were seen with chronological year and disease duration.

Conclusion: A substantial proportion of patients remain in moderate disease, emphasizing the need for treat-to-target strategies for RA patients.

Keywords: Clinical Disease Activity Index; Disease activity; Markov model; Prediction; Rheumatoid arthritis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Transition probabilities for the 3-state model of disease severity. π probability, LL transition from low to low activity, LS transition from low to severe activity, LM transition from low to moderate activity, MM transition from moderate to moderate activity, ML transition from moderate to low activity, MS transition from moderate to severe activity, SM transition from severe to moderate activity, SL transition from severe to low activity, SS transition from severe to severe activity
See this image and copyright information in PMC

References

    1. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012;51(Suppl 5):v3–11. doi: 10.1093/rheumatology/kes113. - DOI - PubMed
    1. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 2012;51 Suppl 6:vi28–36. - PubMed
    1. Singh JA, Saag KG, Bridges SL, Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26. doi: 10.1002/art.39480. - DOI - PubMed
    1. Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, van de Laar MA, van Riel PL. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011;50(1):196–203. doi: 10.1093/rheumatology/keq325. - DOI - PubMed
    1. Uhlig T, Lie E, Norvang V, Lexberg AS, Rodevand E, Kroll F, Kalstad S, Olsen IC, Kvien TK. Achievement of remission and low disease activity definitions in patients with rheumatoid arthritis in clinical practice: Results from the NOR-DMARD Study. J Rheumatol. 2016;43(4):716–23. doi: 10.3899/jrheum.151132. - DOI - PubMed

Publication types